New pill shows promise for rare blood disorder
NCT ID NCT07149818
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 17 times
Summary
This study tests a new oral drug, linprixel, in 22 adults with autoimmune hemolytic anemia that has not responded to or returned after other treatments. The drug aims to control the disease by reducing the immune system's attack on red blood cells. Participants take the drug daily for up to 12 weeks, with possible dose adjustments based on response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.